These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 26577691)

  • 21. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
    Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eprenetapopt Plus Azacitidine in
    Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
    J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
    Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
    Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes.
    Press KR; Uy N; Keefer J; Gore SD; Carraway HE; Sakoian S; Prebet T
    Leuk Lymphoma; 2018 Mar; 59(3):755-757. PubMed ID: 28738707
    [No Abstract]   [Full Text] [Related]  

  • 25. The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
    Akimoto M; Sakurai A; Nishiyama-Fujita Y; Ito C; Aisa Y; Nakazato T
    Ann Hematol; 2021 Apr; 100(4):953-957. PubMed ID: 33521864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
    Thepot S; Boehrer S; Seegers V; Prebet T; Beyne-Rauzy O; Wattel E; Delaunay J; Raffoux E; Hunault M; Jourdan E; Chermat F; Sebert M; Kroemer G; Fenaux P; Adès L;
    Leuk Res; 2014 Dec; 38(12):1430-4. PubMed ID: 25449687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
    Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
    Pleyer L; Döhner H; Dombret H; Seymour JF; Schuh AC; Beach CL; Swern AS; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
    Fujimaki K; Miyashita K; Kawasaki R; Tomita N
    Eur J Haematol; 2016 Sep; 97(3):228-31. PubMed ID: 26613362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
    Savona MR; Kolibaba K; Conkling P; Kingsley EC; Becerra C; Morris JC; Rifkin RM; Laille E; Kellerman A; Ukrainskyj SM; Dong Q; Skikne BS
    Am J Hematol; 2018 Oct; 93(10):1199-1206. PubMed ID: 30016552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
    Müller-Thomas C; Schuster T; Peschel C; Götze KS
    Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
    Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience.
    Onec B; Okutan H; Albayrak M; Can ES; Aslan V; Koluman BU; Kosemehmetoglu OS; Albayrak A
    J Cancer Res Ther; 2018; 14(5):1105-1111. PubMed ID: 30197357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
    Strati P; Kantarjian H; Ravandi F; Nazha A; Borthakur G; Daver N; Kadia T; Estrov Z; Garcia-Manero G; Konopleva M; Rajkhowa T; Durand M; Andreeff M; Levis M; Cortes J
    Am J Hematol; 2015 Apr; 90(4):276-81. PubMed ID: 25530214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
    Abaza YM; Kadia TM; Jabbour EJ; Konopleva MY; Borthakur G; Ferrajoli A; Estrov Z; Wierda WG; Alfonso A; Chong TH; Chuah C; Koh LP; Goh BC; Chang JE; Durkes DE; Foudray MC; Kantarjian HM; Dong XQ; Garcia-Manero G
    Cancer; 2017 Dec; 123(24):4851-4859. PubMed ID: 28841236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.
    Bouchla A; Thomopoulos TP; Papageorgiou SG; Apostolopoulou C; Loucari C; Mpazani E; Pappa V
    Epigenomics; 2021 Jul; 13(14):1129-1143. PubMed ID: 34291653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada.
    Mozessohn L; Cheung MC; Fallahpour S; Gill T; Maloul A; Zhang L; Lau O; Buckstein R
    Br J Haematol; 2018 Jun; 181(6):803-815. PubMed ID: 29767427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia.
    Qu W; Lu J; Ji Y; He Z; Hou M; Li D; Yang Y; Liu D; Chen S
    Cancer Chemother Pharmacol; 2024 Oct; 94(4):635-639. PubMed ID: 38430306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
    DiNardo CD; Olin R; Wang ES; Skikne B; Rosenthal J; Kumar P; Sumi H; Hizukuri Y; Hong Y; Patel P; Seki T; Duan T; Lesegretain A; Andreeff M
    Cancer Med; 2024 Jul; 13(14):e70028. PubMed ID: 39030997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.